Trending Stock News

Tekla Capital Management Cut Position in Puma Biotechnology (PBYI) as Stock Value Declined; As Target (TGT) Stock Declined, Cambridge Financial Group Has Increased Its Stake

Cambridge Financial Group Inc increased its stake in Target Corp (TGT) by 6.95% based on its latest 2017Q3 regulatory filing with the SEC. Cambridge Financial Group Inc bought 7,035 shares as the company’s stock declined 14.90% while stock markets rallied. The institutional investor held 108,279 shares of the department and specialty retail stores company at the end of 2017Q3, valued at $6.39B, up from 101,244 at the end of the previous reported quarter. Cambridge Financial Group Inc who had been investing in Target Corp for a number of months, seems to be bullish on the $41.15B market cap company. The stock decreased 0.45% or $0.34 during the last trading session, reaching $75.7. About 4.28M shares traded. Target Corporation (NYSE:TGT) has declined 16.51% since February 17, 2017 and is downtrending. It has underperformed by 33.21% the S&P500.

Tekla Capital Management Llc decreased its stake in Puma Biotechnology Inc. (PBYI) by 47.91% based on its latest 2017Q3 regulatory filing with the SEC. Tekla Capital Management Llc sold 97,042 shares as the company’s stock declined 6.09% while stock markets rallied. The institutional investor held 105,495 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $12.63 million, down from 202,537 at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Puma Biotechnology Inc. for a number of months, seems to be less bullish one the $2.52B market cap company. The stock decreased 1.54% or $1.05 during the last trading session, reaching $67.05. About 509,765 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 23.65% since February 17, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on March, 7. They expect $-2.04 earnings per share, 0.00% or $0.00 from last year’s $-2.04 per share. After $-2.07 actual earnings per share reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -1.45% EPS growth.

Tekla Capital Management Llc, which manages about $1.06B and $2.80B US Long portfolio, upped its stake in Wright Medical Group N.V. by 52,000 shares to 266,781 shares, valued at $6.90M in 2017Q3, according to the filing. It also increased its holding in Dexcom Inc. (NASDAQ:DXCM) by 23,400 shares in the quarter, for a total of 107,900 shares, and has risen its stake in Accelerate Diagnostics Inc. (NASDAQ:AXDX).

Since September 6, 2017, it had 0 insider purchases, and 6 sales for $4.70 million activity. AUERBACH ALAN H also sold $991,683 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) on Monday, January 22. On Monday, January 22 the insider EYLER CHARLES R sold $62,117. The insider Lo Steven sold $172,515.

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Puma Biotechnology Inc had 57 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating given on Tuesday, March 29 by RBC Capital Markets. J.P. Morgan maintained the shares of PBYI in report on Wednesday, October 4 with “Buy” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, November 10. Credit Suisse maintained it with “Outperform” rating and $142 target in Friday, November 10 report. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Leerink Swann on Wednesday, July 19. As per Wednesday, August 9, the company rating was maintained by J.P. Morgan. The firm earned “Overweight” rating on Thursday, August 27 by JP Morgan. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Stifel Nicolaus on Sunday, September 10. On Monday, October 9 the stock rating was maintained by Bank of America with “Buy”.

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It is positive, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. First Tru Advsrs Lp holds 4,586 shares. Emerald Advisers Pa holds 1.8% or 370,035 shares. Moreover, Sivik Global Ltd Limited Liability Company has 0.81% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Schroder Mngmt Grp, Maine-based fund reported 346,369 shares. Amalgamated Retail Bank holds 0.01% or 3,656 shares. Teacher Retirement System Of Texas accumulated 0% or 2,446 shares. Swiss Bancorporation reported 49,030 shares or 0.01% of all its holdings. Sei Invests holds 0% or 2,140 shares. Schwab Charles Inv Mgmt Inc invested in 135,167 shares or 0.01% of the stock. Pointstate Cap LP owns 0.42% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 414,010 shares. Castleark Limited Liability reported 36,185 shares stake. Great West Life Assurance Can holds 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI) or 3,009 shares. Envestnet Asset Management stated it has 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Federated Investors Inc Pa invested 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Barclays Plc holds 187,549 shares.

Leave a Reply

Your email address will not be published. Required fields are marked *